Background: Papillary thyroid carcinoma (PTC) is considered the most prevalent thyroid malignancy. The association between Hashimoto’s thyroiditis (Ht) and(PTC) is still unclear. Objective: We aimed to examine the clinicopathological impact of mmunohistochemical staining of FOXP3 and Cytokeratin 19 in PTC and concomitant Ht and their correlation with patients’ outcome and survival. Methods: Eighty thyroid biopsies obtained from patients with PTC were immunostained by FOXP3 and CK19.The patients were treated by radioactive iodine (I 131) and followed up. Results : FOXP3 and CK19 expression were detected in 45% and 80% studied cases of PTC respectively. 16.7% of PTC with associated HT showed FOXP3+lymphocytes in lymphocytic infiltrate of HT, while most of PTC associated HT express cytoplasmic CK19 positive Hurtle cells. FOXP3 was more expressed in PTC female patients more than 45 years with higher stage, lymph node, and distant metastasis, extracapsular extension, number of i131doses, and cumulative radioiodine doses with a highly statistically significant difference (p < 0.001). The relation was significant between CK19 immunostaining as regard 10-year Overall Survival and death (p value = 0.027 and 0.036, respectively). Conclusions: HT represents a step in the process of autoimmune inflammatory disease ending by the evolution of PTC with better prognosis; therefore appropriate follow up of these cases is needed. FOXP3 tends to be more expressed in PTC cases with worse prognostic variables and is predictable to become a recent prognostic and targeted therapy for (PTC). There was a significant relation between CK19 immunostaining and 10 year overall survival.